| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7695734 | BOEHRINGER INGELHEIM | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
Apr, 2028
(4 years from now) | |
| US8679533 | BOEHRINGER INGELHEIM | Pramipexole once-daily dosage form |
Sep, 2029
(5 years from now) | |
Mirapex Er is owned by Boehringer Ingelheim.
Mirapex Er contains Pramipexole Dihydrochloride.
Mirapex Er has a total of 2 drug patents out of which 0 drug patents have expired.
Mirapex Er was authorised for market use on 19 February, 2010.
Mirapex Er is available in tablet, extended release;oral dosage forms.
Mirapex Er can be used as treatment of parkinson's disease.
The generics of Mirapex Er are possible to be released after 08 September, 2029.
Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 February, 2010
Treatment: Treatment of parkinson's disease
Dosage: TABLET, EXTENDED RELEASE;ORAL
MIRAPEX ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic